InspireMD

Stent System Technology for Preventing Embolization

Health Tech & Life Sciences
Public on NYSE on Apr 2011

Company Overview

Snapshot

Founded in April 2005, InspireMD operates with 51–200 employees and has raised a total of $229.48 million across 11 funding rounds from 5 investors. In August 2025, the company secured funding from lead investors OrbiMed and Marshall Wace.

Business overview

InspireMD is a commercial-stage medical device company specializing in proprietary stent designs with integrated embolic prevention systems (EPS) for neurovascular protection and stroke prevention. The company's core technology, MicroNet mesh, addresses the limitations of conventional carotid stenting and surgery. InspireMD aims to establish its MicroNet technology as the industry standard for sustained embolic protection and is expanding its portfolio to include applications in other indications such as peripheral artery procedures, serving the healthcare and medical device sectors.

Strategic signal

In October 2024, InspireMD announced the establishment of its global headquarters in Miami, Florida. This strategic move is intended to support the anticipated U.S. launch and commercialization of the CGuard Prime Carotid Stent System, signaling a significant focus on expanding its market presence and operational capabilities within the United States.

Company Intelligence Q&A

What was a key strategic partnership for InspireMD in 2022?
In September 2022, InspireMD announced a strategic outsourcing partnership with NAMSA to accelerate new product development.
What significant regulatory step did InspireMD take in September 2024?
In September 2024, InspireMD submitted a Premarket Approval Application to the FDA, seeking U.S. regulatory approval for its CGuard™ Prime Carotid Stent System.
What was a notable leadership change at InspireMD in November 2025?
In November 2025, InspireMD named Peter A. Soukas, M.D., as its Chief Medical Officer.
What was a key development regarding InspireMD's CGuard EPS in November 2023?
In November 2023, InspireMD announced a strategic agreement with Jacobs Institute to execute an early feasibility study of the CGuard EPS for the treatment of acute stroke patients with tandem lesions.
What was the outcome of InspireMD's third quarter 2025 financial results?
In November 2025, InspireMD reported a Q3 loss but topped revenue estimates, with its Q3 2025 earnings call highlighting robust revenue growth amid rising expenses.

External links